Redeye comments on Thunderful Group’s Q4’24 report, which came in better than expected in terms of s...
VibroSense redovisade en nettoomsättning om 0,46 MSEK (0,57) i kvartalet, vilket var en minskning me...
CapMan’s underlying performance in Q4 was solid and slightly above our estimates.
Redeye provides an update on Xspray Pharma following its year-end report, which revealed no major su...
Atria reported Q4 adjusted EBIT of EUR 13.2m, 19% (EUR 3.
Redeye provides an update following Neola Medical’s Q4 2024 report.
NoHo Partners' Q4 2024 results came in clearly above Vara Research consensus, as the company continu...
Small beat in Q4 and news of CEO leaving Adj. EBITDA up 2.
On February 12th, Eevia Health Plc (publ) (“Eevia”) announced that the Company has signed a term she...
Etteplan’s Q4 performance aligned with our expectations.
Marimekko reports its Q4/24 figures on 19th of February.
Q4 report Wednesday, 19 February at 08:30 CET '24e EBITA up 4% 25-9x EBITA in '24e-'26e, 5-18% FCF y...
NoHo Partners reported Q4 EBIT of EUR 15.1m (+42%% y/y), 19% above Vara Research consensus and 13% a...
Taaleri’s group continuing earnings grew 6% y/y to EUR 10.
Sprint Bioscience delivered Q4 sales within the recent range at SEK 16.
